Studies have shown that DNM1L expression is elevated in lung adenocarcinoma, hepatocellular carcinoma, breast cancer, and head and neck cancer, and it is correlated with poor patient prognosis (18–21). This evidence concerns the gene DNM1L and breast carcinoma.